Compare · CELG~ vs HCXY
CELG~ vs HCXY
Side-by-side comparison of Celgene Corporation (CELG~) and Hercules Capital, Inc. (HCXY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CELG~ and HCXY operate in n/a (n/a), so they compete in similar markets.
- HCXY carries a market cap of $4.55B.
- HCXY has hit the wire 5 times in the past 4 weeks while CELG~ has been quiet.
Latest CELG~
- FDA Approval for REBLOZYL issued to CELGENE CORP
- FDA Approval for REBLOZYL issued to CELGENE CORP
- FDA Approval for REBLOZYL issued to CELGENE CORP
- FDA Approval for IDHIFA issued to CELGENE CORP
- March 27, 2021 - FDA Approves First Cell-Based Gene Therapy for Adult Patients with Multiple Myeloma
- Sutro Biopharma Announces Appointment of Jon M. Wigginton, M.D., to Board of Directors
- Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer
- Global Stem Cells Market is estimated to account for US$ 18,289.9 Mn by end of 2027, Says Coherent Market Insights (CMI)
Latest HCXY
- Hercules Capital Reports Second Quarter 2026 Financial Results
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the Second Quarter 2026
- Hercules Capital Closes Institutional Notes Offering of $325.0 Million 6.300% Unsecured Notes due 2031
- Hercules Capital Prices Institutional Notes Offering of $325.0 Million 6.300% Notes due 2031
- Hercules Capital Announces Date for Release of Second Quarter 2026 Financial Results and Conference Call
- Hercules Capital Announces Date of 2026 Annual Meeting of Stockholders
- Hercules Capital Reports First Quarter 2026 Financial Results
- Hercules Capital Enters Next Phase of Growth with Expanded Leadership Team
- Hercules Capital Declares a Total Cash Distribution of $0.47 per Share for the First Quarter 2026
- Hercules Capital Announces Date for Release of First Quarter 2026 Financial Results and Conference Call